Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

ADMA Biologics Inc

Healthcare US ADMA

7.76USD
0.16(2.11%)

Last update at 2026-06-03T20:00:00Z

Day Range

7.467.79
LowHigh

52 Week Range

7.2125.67
LowHigh

Fundamentals

  • Previous Close 7.60
  • Market Cap2567.36M
  • Volume2920202
  • P/E Ratio17.97
  • Dividend Yield-%
  • EBITDA199.54M
  • Revenue TTM510.17M
  • Revenue Per Share TTM2.14
  • Gross Profit TTM 292.76M
  • Diluted EPS TTM0.60

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 182.66M 125.71M -28.23900M -65.90395M -71.64762M
Minority interest - - - - -
Net income 146.93M 197.67M -28.23900M -85.18332M -84.45288M
Selling general administrative 91.58M 74.12M 57.38M 70.30M 55.19M
Selling and marketing expenses - - - - -
Gross profit 292.76M 219.55M 88.94M 35.27M 1.17M
Reconciled depreciation 8.10M 8.04M 8.16M 7.11M 5.50M
Ebit 189.77M 139.64M -3.21200M -39.36508M -58.37374M
Ebitda 197.86M 147.69M 5.12M -39.23928M -57.87543M
Depreciation and amortization 8.10M 8.04M 8.33M 0.13M 0.50M
Non operating income net other - - - -7.25950M -0.21704M
Operating income 191.44M 138.98M 21.63M -39.36508M -58.37374M
Other operating expenses 318.73M 287.47M 236.58M 193.44M 139.32M
Interest expense 7.11M 13.93M 25.03M 19.28M 13.06M
Tax provision 35.73M -71.95900M 0.00000M - -
Interest income 1.87M 2.10M 1.01M 0.04M 0.03M
Net interest income -5.23900M -11.83300M -23.54229M -19.23454M -13.02230M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 35.73M -71.95900M 8.16M 19.28M 12.81M
Total revenue 510.17M 426.45M 258.21M 154.08M 80.94M
Total operating expenses 101.32M 80.57M 67.31M 74.63M 59.55M
Cost of revenue 217.41M 206.90M 169.27M 118.81M 79.77M
Total other income expense net -8.78700M -13.26900M -49.87100M -26.53887M -13.27388M
Discontinued operations - - - - -
Net income from continuing ops 146.93M 197.67M -22.82615M -65.90395M -71.64762M
Net income applicable to common shares - - - -65.90395M -71.64762M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 624.24M 488.68M 329.18M 348.46M 276.25M
Intangible assets 0.63M 0.46M 0.50M 1.01M 1.73M
Earning assets - - - - -
Other current assets 13.99M 8.03M 5.33M 5.10M 4.34M
Total liab 146.92M 139.66M 193.98M 196.49M 135.08M
Total stockholder equity 477.32M 349.02M 135.21M 151.97M 141.17M
Deferred long term liab - - - - -
Other current liab 41.71M 30.48M 32.92M 24.99M 17.21M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings -161.65300M -308.58300M -506.25600M -478.01667M -412.11272M
Other liab - - - 3.68M 2.37M
Good will 3.53M 3.53M 3.53M 3.53M 3.53M
Other assets - - 0.00000M 4.77M 4.07M
Cash 87.63M 103.15M 51.35M 86.52M 51.09M
Cash and equivalents - - - - -
Total current liabilities 69.54M 55.54M 49.81M 39.27M 30.38M
Current deferred revenue 1.41M 0.14M 0.18M 0.14M 0.14M
Net debt -7.74500M -21.03100M 90.07M 67.92M 51.83M
Short term debt 3.91M 1.22M 1.04M 0.91M 0.59M
Short long term debt 2.81M - - - -
Short long term debt total 79.89M 82.12M 141.42M 154.44M 102.92M
Other stockholder equity 638.95M 657.58M 641.44M 629.97M 553.27M
Property plant equipment - - - 58.26M 50.94M
Total current assets 466.51M 331.41M 257.01M 270.40M 208.73M
Long term investments - - - - -
Net tangible assets - - - 151.97M 141.17M
Short term investments - - - - -
Net receivables 158.43M 50.00M 27.42M 15.51M 28.58M
Long term debt 69.33M 72.34M 130.59M 142.83M 94.87M
Inventory 206.47M 170.24M 172.91M 163.28M 124.72M
Accounts payable 22.52M 20.22M 15.66M 13.23M 12.43M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -478.01667M -412.11272M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 8.60M 5.66M 4.67M 4.77M 4.07M
Deferred long term asset charges - - - - -
Non current assets total 157.73M 157.27M 72.17M 78.06M 67.52M
Capital lease obligations 7.74M 9.78M 10.82M 11.61M 8.05M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -8.57500M -7.32231M -13.91117M -13.51126M
Change to liabilities - - - 7.83M 9.92M
Total cashflows from investing activities -21.89100M -8.57500M -4.98100M -13.91117M -13.51126M
Net borrowings -0.93800M -60.00000M -23.60100M 48.97M -0.03430M
Total cash from financing activities -44.02200M -58.30200M -38.98900M 108.85M 121.05M
Change to operating activities - - - 6.40M 5.49M
Net income 146.93M 197.67M -28.23900M -65.90395M -71.64762M
Change in cash -15.51700M 51.80M -35.17000M 35.43M -4.83203M
Begin period cash flow 103.15M 51.35M 86.52M 51.09M 55.92M
End period cash flow 87.63M 103.15M 51.35M 86.52M 51.09M
Total cash from operating activities 50.40M 118.67M 8.80M -59.50826M -112.36898M
Issuance of capital stock - 0.00000M 0.00000M 64.65M 121.14M
Depreciation 8.10M 8.04M 8.33M 7.11M 5.50M
Other cashflows from investing activities -0.31600M -0.34900M -0.21000M - -
Dividends paid - - - - -
Change to inventory -36.23000M 2.67M -9.62600M -38.55596M -43.18849M
Change to account receivables -108.43000M -22.57800M -11.91600M 13.07M -15.33957M
Sale purchase of stock -31.94000M - -1.41500M 64.82M 121.14M
Other cashflows from financing activities -11.89100M -5.79600M -13.97300M 144.24M -0.06160M
Change to netincome - - - 15.31M 3.71M
Capital expenditures 22.57M 8.57M 4.98M 13.91M 13.51M
Change receivables - - - 13.07M -15.33957M
Cash flows other operating - - - -0.63343M -3.06798M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 35.43M -4.83203M
Change in working capital -139.59500M -18.53900M -10.12300M -18.28526M -51.68042M
Stock based compensation 20.03M 13.62M 6.19M 5.21M 3.49M
Other non cash items 3.92M 2.16M 32.64M 12.35M 1.75M
Free cash flow 27.82M 110.10M 3.82M -73.41943M -125.88024M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ADMA
ADMA Biologics Inc		 0.16 2.11% 7.76 17.97 28.99 5.03 5.30 4.94 12.75
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics Inc

465 State Route 17, Ramsey, NJ, United States, 07446

Key Executives

Name Title Year Born
Mr. Adam S. Grossman Co-Founder, Pres, CEO & Director 1977
Dr. Jerrold B. Grossman D.P.S., Ph.D. Co-Founder & Vice Chairman 1948
Mr. Brian Lenz CPA, CPA Exec. VP, CFO & GM of ADMA BioCenters 1972
Ms. Kaitlin Kestenberg VP of Compliance, Project Management & Clinical Operations NA
Mr. Michael Goldstein Sr. Director & Gen. Counsel NA
Mr. Michael Least VP of Sales & Commercial Operations NA
Mr. Drew Pantello VP of Marketing & Corp. Devel. NA
Mr. Neal C. Fitzpatrick VP of Sales NA
Dr. Gene A. Wetzstein BCOP, Pharm.D. Exec. Director & Head of Scientific Engagement NA
Ms. Cyndi Tolman Sr. VP of Plasma Services NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions